louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05815563: Validation of Peripheral Perfusion Index in Predicting Successful Supraclavicular Brachial Plexus Block in Pediatrics
Official title: Validation of Peripheral Perfusion Index in Predicting Successful Supraclavicular Brachial Plexus Block for Upper Extremity Procedures in Children.
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Pediatrics
Anesthesia, Local
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2023-04-18
Enrollment: 59
Sex: ALL
Minimum age (years): 3
Maximum age (years): 14
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: 59 pediatric patients scheduled for elective upper extremity procedures will receive general anesthesia and trained anesthesiologist will perform ultrasound guided supraclavicular brachial plexus block on the ipsilateral side of the procedure.

Brief summary: Few data are available for the PI as a tool for evaluation of peripheral block success in pediatric patients. Furthermore, there is currently no cut-off value defined for the accuracy of the PI in the detection of successful block.

Detailed description: modify plan for intraoperative and postoperative analgesia. Perfusion index is an assessment of the pulsatile strength at a monitoring site; it is calculated by means of pulse oximetry by expressing the pulsatile signal as a percentage of the non pulsatile signal by a specialized probe, both of which are derived from the amount of infrared light absorbed.PI can provide useful information about the peripheral perfusion status of the patients and works as an index for sympathetic stimulation. Recent study suggested that PI could be used as an early and sensitive indicator to assess the development of sympathectomy induced by brachial plexus block in conscious adults; it is more sensitive than other parameters such as changes of skin temperature gradients or mean arterial pressure (MAP)

Eligibility criteria: Inclusion Criteria:

Age group: (3-14) years old. ASA class I-II

Exclusion Criteria:

* Patients with age below 3 year or older than 14 years. Parent refusal. Patients with apparent infection at site of needle insertion. Patients with any coagulation disorder. Patients with known neuropathy or brachial plexus injury. Patients with any cardiac, hepatic, renal or neurological disease

Primary outcomes:
measure: Perfusion index
timeFrame: Intraoperative
Secondary outcomes:
measure: Temperature
timeFrame: Intraoperative
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of Medicine
Study officials:
References:
Clinical trial NCT00866463: A Study to Compare the Blood Levels of Sildenafil Following Administration of an Experimental Tablet vs. the Conventional Oral Tablet in Healthy Subjects
Official title: An Open-Label, Crossover Study In Healthy Volunteers To Evaluate The Pharmacokinetics Of Sildenafil Following Administration Of An Experimental Tablet Of Sildenafil With Or Without Water Relative To Viagra® Conventional Oral Tablet With Water.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Erectile Dysfunction
Keywords: Sildenafil, Pharmacokinetics, Healthy Volunteer
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2009-03-20
Enrollment: 18
Sex: MALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: This study to will compare the blood levels of sildenafil following administration of an experimental tablet vs. the conventional oral tablet.


Eligibility criteria: Inclusion Criteria:

* Healthy males between the ages of 18 and 55 years.
* Body Mass Index of 18 to 30 kg/m2, and a total body weight \>50 kg (110 lbs).

Exclusion Criteria:

* Smoking in excess of the equivalent of 5 cigarettes per day.
* Treatment with an experimental drug within 30 days or sildenafil, vardenafil, tadalfil within 4 days before first study dose.
* Develop blood pressure lowering or experience dizziness, lightheadedness when going from the laying down position to standing position.

Primary outcomes:
measure: Blood levels of sildenafil
timeFrame: 1 Day
Secondary outcomes:
measure: Blood levels of a metabolite of sildenafil
timeFrame: 1 Day
measure: Side Effects
timeFrame: 1 Day
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Pfizer Investigational Site
state: Connecticut
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT05052463: Electrolyte Imbalance Analysis at Intensive Care Unit Admission : Retrospective Study
Official title: Electrolyte Imbalance Analysis at Icu Admission : Retrospective Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Electrolyte Imbalance
Lead sponsor: Kecioren Education and Training Hospital
Sponsor class: OTHER
First posted: 2021-09-22
Enrollment: 824
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: ıcu patients

Brief summary: The type and severity of electrolyte imbalance in patients admitted to the intensive care unit were analyzed.It was evaluated whether these results had an effect on mortality, length of hospital stay, APACHE II scores and ventilator days


Eligibility criteria: Inclusion Criteria: all of the ıcu patients -

Exclusion Criteria:

-

Primary outcomes:
measure: The analysis the electrolyte imbalance in ICU and the relationship between the icu prognosis.
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Ankara Kecioren Training and Research Hospital
state: Çankaya
Study officials:
References:
Clinical trial NCT03333863: Bacterial and Antimicrobial Susceptibility Profile and the Prevalence of Different Sites of Infection(BASPP)
Official title: Bacterial and Antimicrobial Susceptibility Profile and the Prevalence of Different Sites of Infection in Shengjing Hospital of China Medical University: a Retrospective, Descriptive Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Infectious Diseases in Pneumonia,Nephropyelitis,Angiocholitis or Others
Positive Bacterial Cultures Results of the Medical Records
Lead sponsor: Shengjing Hospital
Sponsor class: OTHER
First posted: 2017-11-07
Enrollment: 1889
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients hospitalized with positive bacterial cultures results in blood, urine, sputum, and secretion, are enrolled at shengjing hospital of China Medical University from January 2015 to December 2017.

Brief summary: Positive results of bacterial culture are analyzed comprehensively in Shengjing Hospital of China Medical University in recent 3 years（between 2015- 2017）


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of pneumonia, nephropyelitis, angiocholitis or other infectious diseases
* Positive results of bacterial cultures in blood, urine, sputum, and secretion
* The medical records of shengjing hospital of China Medical University from January 2015 to December 2017

Exclusion Criteria:

* Negative results of bacterial cultures in blood, urine, sputum, and secretion

Primary outcomes:
measure: bacterial and antimicrobial susceptibility profile
timeFrame: From January 2015 to December 2017
Secondary outcomes:
measure: patient's critical condition
timeFrame: From January 2015 to December 2017
Other outcomes:
Locations:
city: Shenyang
country: China
facility: Shengjing hospital of China Medical University
state: Liaoning
Study officials:
affiliation: Shengjing Hospital
name: Hongyu Zhao, doctor
role: PRINCIPAL_INVESTIGATOR
References:
citation: Musicha P, Cornick JE, Bar-Zeev N, French N, Masesa C, Denis B, Kennedy N, Mallewa J, Gordon MA, Msefula CL, Heyderman RS, Everett DB, Feasey NA. Trends in antimicrobial resistance in bloodstream infection isolates at a large urban hospital in Malawi (1998-2016): a surveillance study. Lancet Infect Dis. 2017 Oct;17(10):1042-1052. doi: 10.1016/S1473-3099(17)30394-8. Epub 2017 Aug 14.
Clinical trial NCT04178863: CATS Tonometer IOP Reduction Latanoprost Verses Timolol
Official title: Efficacy of Topical Latanoprost 0.005% Verses Timolol 0.5% Demonstrated by Corneal Biomechanical Correcting Modified Goldmann Prism
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Glaucoma; Drugs
Lead sponsor: Intuor Technologies, Inc.
Sponsor class: INDUSTRY
First posted: 2019-11-26
Enrollment: 72
Sex: ALL
Minimum age (years): 18
Maximum age (years): 101
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Topical Prostaglandin Analog vs Betablocker - Corneal Biomechanical Evaluation using CATS Tonometer Prism

Detailed description: This clinical trial is a prospective, controlled, study and will be performed at one clinical investigative site in Tucson Arizona1. The purpose of this study is to determine if the device, CATS tonometer prism, measures intraocular pressure significantly differently than the current standard of care tonometer prism (Goldmann) before and after institution of topical prostaglandin analogs (PGA) for glaucoma treatment. Fifty percent of patients will be randomly placed on topical beta blockers as a control. The difference PGAs and beta blockers would be a measurement of the amount of corneal biomechanical changes made due to the PGA controlled for the effect of IOP lowering by the beta -blocker group.

Eligibility criteria: Inclusion Criteria:

* • Male and female patients, at least 18 years of age

  * Subject has a clear understanding and agrees to all the conditions of the informed consent form

Exclusion Criteria:

* Subjects shall be selected in accordance with the following exclusion criteria

  * Subject has undergone ocular surgery within the last 3 months
  * Uncontrolled systemic disease that in the opinion of the Investigator would put the subject's heath at risk
  * Pregnant or nursing women
  * Those who have had corneal surgery including corneal laser surgery
  * Microphthalmos
  * Buphthalmos
  * Severe Dry eyes
  * Lid squeezers - blepharospasm
  * Nystagmus
  * corneal or conjunctival infection.

Primary outcomes:
measure: IOP reduction
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Tucson
country: United States
facility: Arizona Eye Consultants
state: Arizona
Study officials:
References:
citation: Radcliffe N, Berdahl J, Ibach M, Schweitzer J, Levine J, McCafferty S. Improved Efficacy of Topical Latanoprost 0.005% Demonstrated by Corneal Biomechanical Correcting Modified Goldmann Prism. Clin Ophthalmol. 2020 Aug 10;14:2245-2253. doi: 10.2147/OPTH.S264055. eCollection 2020.
Clinical trial NCT00297063: BRL49653C In Type 2 Diabetes -Comparison Study With Pioglitazone And Placebo By Monotherapy-
Official title: Clinical Evaluation of Rosiglitazone Malate (BRL49653C) in Patients With Type 2 Diabetes Mellitus (Monotherapy) - Double-Blind Comparative Study of Rosiglitazone Maleate vs. Pioglitazone Hydrochloride and Placebo -
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Diabetes Mellitus, Type 2
Keywords: rosiglitazone
vandia
Type 2 diabetes mellitus
diabetes;
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2006-02-27
Enrollment: 350
Sex: ALL
Minimum age (years): 20
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is designed to compare the efficacy and safety of BRL49653C versus pioglitazone and placebo.


Eligibility criteria: Inclusion criteria:

* Type 2 diabetes mellitus.
* Managed by diet therapy.
* Must have adequate blood, liver and kidney function.

Exclusion criteria:

* Serious cardiovascular disease or serious hepatic disease.

Primary outcomes:
measure: HbA1c change from baseline at Week 28.
timeFrame: 28 Weeks
Secondary outcomes:
measure: Efficacy variables (changes from baseline in FPG, fasting insulin, HOMA-IR and HOMA-beta) at stipulated date in each treatment group.
timeFrame: 28 Weeks
Other outcomes:
Locations:
city: Fukuoka
country: Japan
facility: GSK Investigational Site
city: Fukushima
country: Japan
facility: GSK Investigational Site
city: Hokkaido
country: Japan
facility: GSK Investigational Site
city: Ibaraki
country: Japan
facility: GSK Investigational Site
city: Kanagawa
country: Japan
facility: GSK Investigational Site
city: Kyoto
country: Japan
facility: GSK Investigational Site
city: Nagano
country: Japan
facility: GSK Investigational Site
city: Osaka
country: Japan
facility: GSK Investigational Site
city: Saitama
country: Japan
facility: GSK Investigational Site
city: Shizuoka
country: Japan
facility: GSK Investigational Site
city: Tokyo
country: Japan
facility: GSK Investigational Site
city: Tokyo
country: Japan
facility: GSK Investigational Site
city: Tokyo
country: Japan
facility: GSK Investigational Site
facility: GSK Investigational Site
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References:
citation: Kikuchi M, Kaku K, Odawara M, Momomura S, Ishii R. Efficacy and tolerability of rosiglitazone and pioglitazone in drug-naive Japanese patients with type 2 diabetes mellitus: a double-blind, 28 weeks' treatment, comparative study. Curr Med Res Opin. 2012 Jun;28(6):1007-16. doi: 10.1185/03007995.2012.694361. Epub 2012 Jun 6.
citation: MacDonald MR, Petrie MC, Home PD, Komajda M, Jones NP, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, Curtis PS, McMurray JJ. Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes Care. 2011 Jun;34(6):1394-6. doi: 10.2337/dc10-2398. Epub 2011 May 11.
Clinical trial NCT00432263: Treatment Of Adult Growth Hormone Deficiency After Traumatic Brain Injury.
Official title: Placebo-Controlled Trial On The Efficacy Of Growth Hormone Replacement Therapy In Patients With Growth Hormone Deficiency After Traumatic Brain Injury
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Brain Injuries
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2007-02-07
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To establish the effects of genotropin replacement in patients with severe growth hormone deficiency after traumatic brain injury on cognitive function.


Eligibility criteria: Inclusion Criteria:

* Have had a previous traumatic brain injury (more than 1 year and less than 5 years) prior to the screening visit.
* Have an Extended Glasgow Outcome Scale (GOS-E) more than or equal to 5.

Exclusion Criteria:

* Active systemic malignancy or active intracranial tumor. A successfully treated tumor or malignancy is not an exclusion criterion if the patient has not had active disease for 5 years and is not currently receiving maintenance chemotherapy, (except for basal cell skin cancers.
* Receiving treatment with prednisolone in doses above 10 mg/day or treatment with other oral glucocorticosteroids above replacement doses is not permitted throughout the study. Topical and inhaled corticosteroids are permitted.

Primary outcomes:
measure: The primary endpoint is the change from baseline in the CogState™ composite score at Week 36.
Secondary outcomes:
measure: Change CogState™ at Week 12, 24, 60 and 72. Change in lean body mass and fat mass at Week 36 and 72. Change in the Extended Glasgow Outcome Scale at week 36 and 72. Change in quality of life at week 24, 36, 60 and 72. Summary of change in cardiovascular
Other outcomes:
Locations:
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT04874363: The Effects of Smoking on Mortality in Patients With Acute Respiratory Syndrome Coronavirus 2 Infection
Official title: The Effects of Smoking on Mortality in Intensive Care Unit in Patients With Acute Respiratory Syndrome Coronavirus 2 Infection
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Covid19
Smoking
Lead sponsor: Sisli Hamidiye Etfal Training and Research Hospital
Sponsor class: OTHER
First posted: 2021-05-05
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Conditions regarded to the usage of cigarettes will be recorded as patients who are active smokers and patients who do not smoke.

Brief summary: This is a retrospective single centered study that was done in the ICU on patients with Covid-19 between 16th of March -16th of May in 2020 Retrospective records will be examined by examining the electronic data files of the patients.

There were two groups as smoker and non-smoker.

Detailed description: The aims of the present study is to see the effects of smoking prevalence, the length of stay regarding the usage of cigarettes, and the effects on the mortality of COVID-19 in our intensive care unit(ICU).

This is a retrospective single centered study that was done in the ICU on patients with Covid-19 between 16th of March -16th of May in 2020. The demographic data, comorbidity status, the units they were accepted from, clinical symptoms , respiratory support, prevalence of smoking, length of stay in the ICU and mortalities of the patients weill be recorded. There are two groups as smoker and non-smoker.

Eligibility criteria: Inclusion Criteria:

* All the patient's data are diagnosed with acute respiratory syndrome Covid-19 over 18 years old

Exclusion Criteria:

* Patients under 18 years of age

Primary outcomes:
measure: Mortality
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Sisli Hamidiye Etfal Research and Training Hospital
Study officials:
References:
Clinical trial NCT04791163: Above-knee Socket Evaluation : Sub-ischial vs Ischial Containment
Official title: AK Socket Evaluation : Sub-ischial vs Ischial Containment. Multi-center Randomised Crossover Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Lower Limb Amputation Above Knee (Injury)
Lead sponsor: Proteor Group
Sponsor class: INDUSTRY
First posted: 2021-03-10
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Socket is key to provide comfort and function to lower limb amputees. A new socket, the sub-ischial socket, will be compared to "traditional" ischial containment sockets, based on comfort self-evaluation, and locomotor capacities.

Detailed description: Subjects wearing ischail containment sockets will be proposed to enter the research. They will be provided and fitted with a sub-ischial socket. Randomly, they will use one or the other socket for four weeks, then be tested : finctional test and questionnaires. After this testing session, they will use the other socket, and be re-tested accordingly.

Eligibility criteria: Inclusion Criteria:

* can give informed consent
* aged 18 or more
* above-knee amputee, wearing a definitive ischial containment socket
* stump longer than 16cm
* wearing a liner, whatever the suspension system
* able to walk (d4600, d4601, d4602, d4608 accordinf to IFC)
* unilaterla or bilateral amputee
* able to done the socket standing
* whatever the etiology

Exclusion Criteria:

* protected person
* pregnant woman or nursing mother
* subject having comorbidities heavily impacting feeling or socket donning
* allergic to silicon
* suffering from big volume variations in a same day
* infecté stump (may lead to lymphatic problems)

Primary outcomes:
measure: Comfort evaluation
timeFrame: 1 minute
Secondary outcomes:
measure: Comfort evaluation in various situations
timeFrame: 1 minute
measure: Locomotor capability
timeFrame: 5 minutes
Other outcomes:
Locations:
city: Angers
country: France
facility: Les Capucins
city: Bruges
country: France
facility: UGECAM La Tour de Gassies
city: Colomiers
country: France
facility: Clinique du Cabirol
city: Hyères
country: France
facility: Hôpital Léon Bérard
city: Nancy
country: France
facility: UGECAM - IRR Nancy
city: Paris
country: France
facility: Institution Nationale des Invalides
city: Ploemeur
country: France
facility: Centre Mutualiste de Kerpape
city: Saint-Herblain
country: France
facility: UGECAM La Tourmaline
city: Vannes
country: France
facility: CHBA Vannes
Study officials:
References:
Clinical trial NCT05108363: Effect of Obstructive Sleep Apnea on Glucose Control and Cognitive Function
Official title: Effect of Obstructive Sleep Apnea on Glucose Control and Cognitive Function - a Substudy of 'Continuous Glucose Monitoring as an Adjunct to Lifestyle Modification in Individuals With Impaired Glucose Tolerance: a Randomised Controlled Trial'
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Cognitive Change
Lead sponsor: Chinese University of Hong Kong
Sponsor class: OTHER
First posted: 2021-11-04
Enrollment: 0
Sex: ALL
Minimum age (years): 40
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: And lifestyle modification program for 6 months of therapy
Primary purpose: TREATMENT

Brief summary: Obstructive sleep apnea (OSA) may contribute to altered cognitive function in patients suffering from severe OSA. And lifestyle modification program may improve the cognitive function after 6 months of therapy.


Eligibility criteria: Inclusion Criteria:

* BMI ≥ 25kg/m2
* impaired glucose tolerance which defined as plasma glucose at the range of 7.8 and 11 mmol/l 2 hours after 75g oral glucose solution intake,
* willing to participate in lifestyle modification program
* and capable of using continuous glucose monitoring (CGM) as judged by investigator

Exclusion Criteria:

1. Lactating or pregnant,
2. known diabetes, current or previous use of glucose lowering drug
3. current participation in other weight loss or lifestyle interventions, or use of weight loss drugs,
4. current use of steroids
5. uncontrolled thyrotoxicosis
6. allergy to medical grade adhesives
7. known obstructive sleep apnea on continuous positive airway pressure therapy
8. symptoms of cognitive deterioration (according to the Hong Kong Montreal Cognitive Assessment (HK-MoCA) at the score of \<21)
9. predominant central sleep apnea
10. uncontrolled hypertension (blood pressure \>140/90mmHg) or requiring more than two anti-hypertensive medication
11. history of stroke or brain injury,
12. unstable cardiovascular disease (e.g. recent unstable angina or myocardial infarction within the previous 6 months or severe left ventricular failure; neuromuscular disease affecting or potentially affecting respiratory muscles; moderate to severe respiratory disease (i.e. breathlessness affecting activities of daily living) or documented hypoxemia or awake SaO2 \<92%)
13. psychiatric disease that limits the ability to give informed consent or complete the study
14. Use of psychoactive medication.

Primary outcomes:
measure: Change of Montreal Cognitive Assessment (MoCA) score
timeFrame: 12 months
Secondary outcomes:
measure: Change of apnea-hypopnea index
timeFrame: 12 months
Other outcomes:
Locations:
city: Hong Kong
country: China
facility: Prince of Wales Hospital
state: Hong Kong
Study officials:
affiliation: Chinese University of Hong Kong
name: Susanna Ng
role: PRINCIPAL_INVESTIGATOR
References: